Valbenazine and deutetrabenazine are described as having what relationship to low-potency agents?

Valbenazine and deutetrabenazine are described as having what relationship to low-potency agents?

• A. They are more effective with high-potency agents
• B. They are more effective with low-potency agents
• C. They have no interaction with potency
• D. They are only effective with SGAs

Answer: (B)

Valbenazine and deutetrabenazine are VMAT2 inhibitors used to treat tardive dyskinesia. They work by decreasing the packaging and release of dopamine in presynaptic neurons, which lowers dopaminergic stimulation in the striatum and reduces involuntary movements that result from long-term dopamine D2 blockade. Clinical descriptions note that these VMAT2 inhibitors are more effective when tardive dyskinesia arises after exposure to low-potency antipsychotics. The pattern of TD linked to low-potency agents tends to respond well to lowering presynaptic dopamine availability, which is precisely what VMAT2 inhibition achieves. This is why the statement about being more effective with low-potency agents fits best. They’re not limited to high-potency agents, and they’re not restricted to SGAs—their benefit isn't confined to a single class of antipsychotics, even though the described relationship emphasizes TD linked to low-potency drugs.

Valbenazine and deutetrabenazine are VMAT2 inhibitors used to treat tardive dyskinesia. They work by decreasing the packaging and release of dopamine in presynaptic neurons, which lowers dopaminergic stimulation in the striatum and reduces involuntary movements that result from long-term dopamine D2 blockade.

Clinical descriptions note that these VMAT2 inhibitors are more effective when tardive dyskinesia arises after exposure to low-potency antipsychotics. The pattern of TD linked to low-potency agents tends to respond well to lowering presynaptic dopamine availability, which is precisely what VMAT2 inhibition achieves. This is why the statement about being more effective with low-potency agents fits best. They’re not limited to high-potency agents, and they’re not restricted to SGAs—their benefit isn't confined to a single class of antipsychotics, even though the described relationship emphasizes TD linked to low-potency drugs.